Average common and common equivalent shares - diluted (in thousands)
37,231
37,005
36,900
37,006
37,172
Balance Sheet Data as of June 30:
2015
201__4
201__3
201__2
201__1
Cash, cash equivalents and short-term available-for-sale investments
110,921
$
363,354
$
332,937
$
268,986
$
140,813
Working capital
208,515
443,022
377,432
310,757
212,229
Total assets
1,063,360
862,491
778,098
719,324
617,670
Total shareholders’ equity
846,935
795,265
737,541
674,442
586,122
Cash Flow Data:
2015
201__4
201__3
201__2
201__1
Net cash provided by operating activities
$
139,359
$
136,762
$
123,562
$
126,746
$
127,194
Capital expenditures
19,904
13,821
22,454
6,017
3,630
Cash dividends declared per share
1.27
1.23
1.18
1.11
1.07
Employee Data as of June 30:
2015
201__4
201__3
201__2
201__1
Employees
1,356
967
789
783
763
(1)
The Company acquired Novus Holdings LLC (Novus) on July 2, 2014, ProteinSimple on July 31, 2014, and CyVek Inc. on November 3, 2014.
(2)
The Company acquired Bionostics Holdings, Ltd on July 22, 2013 and Shanghai PrimeGene Bio-Tech Co. on April 30, 2014.
(3)
The Company acquired Boston Biochem, Inc. on April 1, 2011 and Tocris Holdings Limited and subsidiaries on April 28, 2011.
(4)
Earnings before income taxes included acquisition related expenses related to amortization of intangibles, costs recognized on sale of acquired inventories and professional fees associated with acquisition activity, as follows: 2015 - $37.6 million; 2014 - $20.0 million; 2013 - $10.2 million; 2012 - $12.7 million; 2011 - $5.0 million; 2010.
filings.tools